Estrogens and male sexuality: Efficiency of antiestrogens in case of hypothalamic hypogonadisme and late onset hypogonadism;Œstrogènes et sexualité masculine: Effets des antiœstrogènes en cas d'hypogonadisme hypothalamique

Revue Medicale Suisse

Volumn 7, Issue 287, 2011, Pages 644-647

  Martin Du Pan, Rémy C ^a  

^a NONE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; CLOMIFENE; LUTEINIZING HORMONE; RALOXIFENE; TESTOSTERONE;

AGING; ANOREXIA; DEPRESSION; ERECTILE DYSFUNCTION; ESTROGEN THERAPY; EXERCISE; GONADAL DISEASE; HUMAN; HYPOTHALAMIC HYPOGONADISM; LATE ONSET HYPOGONADISM; LIBIDO DISORDER; LUTEINIZING HORMONE RELEASE; OBESITY; REVIEW; STRESS; TESTOSTERONE RELEASE; ARTICLE; HYPOGONADISM; HYPOTHALAMUS DISEASE; MALE; SEXUALITY;

ESTROGEN ANTAGONISTS; HUMANS; HYPOGONADISM; HYPOTHALAMIC DISEASES; MALE; SEXUALITY;

EID: 79953857503     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. * Wibowo E, Schellhammer P, Wassersug R. Role of estrogen in normal male function: Clinical implications for patients with prostate cancer on androgen deprivation therapy. J Urol 2011;185:17-23.
2. Davidson JM. Effects of estrogen on the sexual behavior of male rats. Endocrinology 1969;84:1365.
3. Davidson JM, Camargo C Smith ER, et al. Maintenance of sexual function in a castrated man treated with ovarian steroids. Arch Sex Behav 1983;12:263-74. (Pubitemid 13056799)
4. Iversen P. Orchidectomy and œstrogen therapy revisited. Eur Urol 1998;34:7-11.
5. Lamba H, Goldemeier D, Mackie NE, et al. Antiretroviral therapy is associated with sexual dysfunction and with increased serum estradiol levels in men. Int J STD AIDS 2004;15:243-7.
6. Martin-Du Pan R. Déficit en androgènes chez la femme: indications et risques d'un traitement par la testostérone ou la DHEA. Rev Med Suisse 2007;3:792-7.
7. Davis SR, Goldstat R, Papalia MA, et al. Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: A randomized, placebo-controlled trial. Menopause 2006;13:37-45.
8. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994;331:1056-61. (Pubitemid 24317698)
9. Carani C, Rochira V, Faustini-Fustini M, et al. Role of œstrogen in male sexual behaviour: Insights from the natural model of aromatase deficiency. Clin Endocrinol (Oxf) 1999;51:517-24. (Pubitemid 29513321)
10. Klein C, Gorzakla BB. Sexual functioning in transsexuals following hormone therapy and genital surgery: A review. J Sex Med 2009;6:2922.
11. Elaut E, De Cuypere G, De Sutter P, et al. Hypoactive sexual desire in transsexual women; prevalence and association with testosterone levels. Eur J Endocrinol 2008;158:393-9. (Pubitemid 351405005)
12. Luisi M, Franchi F. Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal mal patients. J Endocrinol Invest 1980;3:305-8. (Pubitemid 11218506)
13. Gooren LJ. Human male sexual functions do not require aromatisation of testosterone: A study using tamoxifen, testolactone, and dihydrotestosterone. Arch Sex Behav 1985;14:529-48.
14. Bagateli CJ, Heiman JR, Jean R, et al. Effects of endogenous testosterone and estradiol on sexual behavior in normal young men. J Clin Endocrinol Metab 1994;78:711-6. (Pubitemid 24083316)
15. Tsoundi E, Kourlis A, Famakiolis D, et al. The effect of SERM administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia. Fertil Steril 2009;91(Suppl. 4):1427-30.
16. Wyer AA, Hayes FJ, Pitteloud N, et al. The long-term clinical follow-up and natural history of men with adult-onset idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2010;95:4235-43.
17. Ascoli P, Cavagnini F. Hypopituitarism. Pituitary 2008;9:335-42.
18. Guay AT, Bansal S, Hodge MB. Possible hypothalamic impotence. Male counterpart to hypothalamic amenorrhea? Urology 1991;38:317-22.
19. Whitten SJ, Nangla AK, Kolettis PN. Select patients with hypogonadotropic hypogonadism may respond to treatment with clomiphene citrate. Fertil Steril 2006;86:1664-8.
20. Chavan R, Dwyer AA, Pitteloud N. Male functional hypogonadotropic hypogonadism: A distinct clinical entity? Abstract 31. Rencontre annuelle de la Société suisse d'endocrinologie (18.11.2010).
21. Almeida OP, Yeap BP, Hankey GJ, et al. Low free testosterone concentration as a potentially treatable cause of depressive symptoms in older men. Arch Gen Psychiatry 2008;65:283-9. (Pubitemid 351342444)
22. Schweiger U, Deuschele M, Weber B, et al. Testosterone, gonadotropin, and cortisol secretion in male patients with major depression. Psychsom Med 1999;61:292-6.
23. Misra M, Katzman DK, Cord J, et al. Bone metabolism in adolescent boys with anorexia nervosa J Clin Endocrinol Metab 2008;93:3029-36.
24. Wabitsch M, Ballauff A, Holl R, et al. Serum leptin, gonadotropin, testosterone in male patients with anorexia nervosa during weight gain. J Clin Endocrinol Metab 2001;86:2982-8. (Pubitemid 32673452)
25. MacConnie SE, Barkan A, Lampman RM, et al. Decreased hypothalamic gonadotropin-releasing hormone secretion in male marathon runners. N Engl J Med 1986;315:411-7. (Pubitemid 16075604)
26. Burge MR, Lanzi RA, Skarda ST, et al. Idiopathic hypogonadotropic hypogonadism in a male runner is reversed by clomiphene citrate. Fertil Steril 1997,67:783-5. (Pubitemid 27152394)
27. Strain G, Zumoff B, Rosner W, et al. The relationship between serum levels of insulin and SHBG in men: The effect of weight loss. J Clin Endocrinol Metab 1994;79:1173-6. (Pubitemid 24342268)
28. De Bœr H, et al. Letrozole once a week normalizes serum testosterone in obesity-related hypogonadism. Eur J Endocrinol 2008;158:741-7.
29. Zumoff B, Miller JK, Strain CW. Reversal of the hypogonadotropic hypogonadism of obese men by the aromatase inhibitor testolactone. Metabolism 2003;52:1126-8. (Pubitemid 37203485)
30. Tan RS, Vasudevan D. Use of clomiphene citrate to reverse premature andropause secondary to steroid abuse. Fertil Steril 2003;79:203-5. (Pubitemid 36071263)
31. Kishinmoto T, Watanabe K. Antipsychotic-induced hyperprolactinemia inhibits hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry 2008;69:385-91. (Pubitemid 351549390)
32. Vandekercklove P, Lifford R, Vail A, et al. Clomiphene or tamoxifen for idiopathic oligo/asthenospermia Cochrane Database Syst Rev 2000, CD000151.
33. Guay AT, Jacobson J, Perez JB, et al. Clomiphene increases free T levels in men with both secondary hypogonadism and erectile dysfunction. J Impot Res 2003;15:156-65. (Pubitemid 36928907)
34. Guay AT, Bensal S, Headey GJ. Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: Double blind placebo-controlled trial with clomiphene citrate. J Clin Endocrinol Metab 1995;80:3546-52.
35. * Taylor F, Levine L. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: Efficacy and treatment cost. J Sex Med 2010;7:269-76.
36. * Tajar A, Forti G, O'Neill TW, et al. Characteristics of secondary, primary and compensate hypogonadism in aging men. J Clin Endocrinol Metab 2010;95:1410-8.
37. * Wu FC, Tajar, A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123-35.
38. Lakshman KM, Kaplan B, Travison TG, et al. The effects of injected testosterone dose and age on the conversion of T to estradiol and DHT in young and older men. J Clin Endocrinol Metab 2010;95:3955-64.
39. Abbot RD, Launer LJ, Rodriguez BL, et al. Serum estradiol and risk of stroke in ederly men. Neurology 2007;68:563-8.
40. Muller M, Van den Beld AW, Grobbee DE, et al. Sex hormones and cognitive decline in elderly men. Psychoneuroendocrinology 2009;34:27-31.
41. Maggio M, Lauretani F, Ceda GP, et al. Estradiol and metabolic syndrome in older Italian men: The In CHIANTI study. J Androl 2010;31:155-62.
42. Leder BZ, Rohrer JL, Rubin SD, et al. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab 2004;89:1174-80. (Pubitemid 38368408)
43. Burnett-Bowie SA, McKay EA, Lee H, et al. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab 2009;94:4785-92.
44. Dueschek EJ, Gooren LJ. Comparison of effects of the rise in serum testosterone by raloxifène and oral testosterone on serum IGF-1 and IGF binding protein-3. Maturitas 2005;51:286-93. (Pubitemid 40835949)
45. Uebelhart B, Hermann F, Pavo I, et al. Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels. J Bone Miner Res 2004;19:1518-24. (Pubitemid 41094354)
46. Smith MR, Fallon MA, Lee H, et al. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men prostate cancer: A randomised controlled trial. J Clin Endocrinol Metab 2004;89:3841-6. (Pubitemid 39071482)
47. Smith MR, Morton RA, Barnette KG, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 2010;194:1316-21.
48. Bonkhoff H, Berges R. The evolving role of œstrogens and their receptors in the development and progression of prostate cancer. Eur Urol 2009;55:533-42.
49. Guay AT, Perez JB, Fitaihi WA, et al. Testostereone treatment in hypogonadal men: PSA level and risk of prostate cancer. Endocr Pract 2000;6:218-21.
50. Stein S, Zoltick B, Peacock T, et al. Phase II trial of toremifene in androgen-independent prostate cancer: A Penn cancer clinical trials group trial. Am J Clin Oncol 2001;24:283-5. (Pubitemid 32520636)